検索結果

>ネクセラファーマのセンテッサ持株：ほぼゼロ（少なくとも開示上はなし） Amended and Restated License, Assignment, and Research Services Agreement In January 2019, the Company entered into an exclusive worldwide license agreement with Heptares Therapeutics Limited, or Heptares, to further develop and commercialize, the licensed technology for Orexin Agonist. The Company is responsible for supplying all active pharmaceutical ingredients and finished drug product for exploitation. The Company is obligated to make up to $17.2 million (£12.6 million at an exchange rate of 0.73) in payments upon the achievement of development and regulatory milestones. The Company is also obligated to make future commercial milestone payments at low to mid-single digit royalty rates for net product sales and is subject to adjustment in the event the Company sublicenses the approved technology. In addition, the Company is obligated to fund any development related costs associated with the licensed technology. Upon entering into the license agreement, the Company issued 1,199,151 ordinary shares to Heptares with a nominal value of £0.0001 per share with an estimated fair value of $2.1 million

"An innovative biotech pioneering drug discovery with a world-class platform, specialized in identifying special cyclic peptides in just one month from a repertoire of trillions. We partner with almost all global mega-pharma to develop next-generation therapeutics bridging the gap between small molecules and biologics."